Moxonidine
Brand: Physiotens (EU) / Moxcent (IN) / Moxon (BD)
Antihypertensive
Imidazoline receptor agonist (centrally acting)
Pharmacokinetics
| Half-life | 2.5 hours |
| Tmax | 1 h |
| Bioavailability | 90 % (approx) |
| Protein Binding | 7 % |
| Volume of Distribution | 1.4 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Rapid absorption; bioavailability >85%; excreted mainly unchanged via kidneys; dose adjustment required in renal impairment. |
⚠️ Safety & Warnings
Severity: Mild
Adverse Effects:
Dry mouth, headache, dizziness, fatigue, bradycardia
Contraindications:
Severe bradyarrhythmia, advanced heart block
Precautions:
Monitor heart rate and renal function; avoid abrupt discontinuation; minimal rebound compared to clonidine